We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Polyphosphates May Be the Key to Preventing Thrombosis

By LabMedica International staff writers
Posted on 22 Dec 2009
Researchers have demonstrated that an inorganic polymer, polyphosphate, plays a key role in both inflammation and the formation of blood clots.

Polyphosphates are produced and released by platelets (thrombocytes). They play a key role in blood coagulation, as they activate factor XII, which is essential for blood clot formation. Furthermore, platelet-derived polyphosphates activate a variety of inflammatory substances that contribute to leakage from the blood vessels, which is a characteristic feature of inflammation.

Investigators at the University of Leeds (United Kingdom) and collaborators from several European countries and the United States reported in the December 11, 2009, issue of the journal Cell that activated platelets released inorganic polyphosphate (polyP), a polymer of 60–100 phosphate residues that directly bound to and activated the plasma protease factor XII. Blood clots initiated by polyP formed inside blood vessels (causing thrombosis), but not on the surface of the skin. For this reason the investigators postulate that intervention to prevent polyP formation or factor XII activation could prevent thrombosis without interfering with the healing of wounds.

"Our work suggests polyphosphate or factor XII could be potential new targets, as neither seems to affect our ability to heal naturally, so drugs based on these molecules could offer a major improvement on existing treatments," said contributing author Dr. Nicola Mutch, an independent research fellow at the University of Leeds. "The challenge in designing treatments to reduce thrombosis is getting the balance right. We need to find an appropriate drug level or target which causes enough anticoagulation to prevent risk of heart attack or stroke but with minimal bleeding side effects."

Related Links:
University of Leeds



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
All-in-One Molecular System
AIO M160
Immunofluorescence Analyzer
IFA System

Latest BioResearch News

Circulating Tumor DNA Helps Identify Targets for Personalized Immunotherapy
22 Dec 2009  |   BioResearch

Researchers Classify 108 Lysosomal Disorders in Updated Diagnostic Framework
22 Dec 2009  |   BioResearch

New Autoantibody Target Identified in Neuromyelitis Optica Spectrum Disorder
22 Dec 2009  |   BioResearch